NASDAQ:VRTX   Vertex Pharmaceuticals Incorporated
All risks already in price IMO. Short downtrend most probably soon will change to bullish as fundamental improves.
Triger: latest news about ABBV & Galapagos Phase 2 study in CF

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.